tetano
Editor, Senior Moderator
Sci Rep
. 2024 Feb 24;14(1):4534.
doi: 10.1038/s41598-024-54876-2. Mosaic quadrivalent influenza vaccine single nanoparticle characterization
Rong Sylvie Yang[SUP] #[/SUP][SUP] 1 [/SUP], Maria Traver[SUP] #[/SUP][SUP] 2 [/SUP], Nathan Barefoot[SUP] 1 [/SUP], Tyler Stephens[SUP] 3 [/SUP], Casper Alabanza[SUP] 1 [/SUP], Javier Manzella-Lapeira[SUP] 2 [/SUP], Guozhang Zou[SUP] 1 [/SUP], Jeremy Wolff[SUP] 1 [/SUP], Yile Li[SUP] 1 [/SUP], Melissa Resto[SUP] 1 [/SUP], William Shadrick[SUP] 1 [/SUP], Yanhong Yang[SUP] 1 [/SUP], Vera B Ivleva[SUP] 1 [/SUP], Yaroslav Tsybovsky[SUP] 3 [/SUP], Kevin Carlton[SUP] 1 [/SUP], Joseph Brzostowski[SUP] 2 [/SUP], Jason G Gall[SUP] 1 [/SUP], Q Paula Lei[SUP] 4 [/SUP]
Affiliations
Recent work by our laboratory and others indicates that co-display of multiple antigens on protein-based nanoparticles may be key to induce cross-reactive antibodies that provide broad protection against disease. To reach the ultimate goal of a universal vaccine for seasonal influenza, a mosaic influenza nanoparticle vaccine (FluMos-v1) was developed for clinical trial (NCT04896086). FluMos-v1 is unique in that it is designed to co-display four recently circulating haemagglutinin (HA) strains; however, current vaccine analysis techniques are limited to nanoparticle population analysis, thus, are unable to determine the valency of an individual nanoparticle. For the first time, we demonstrate by total internal reflection fluorescence microscopy and supportive physical-chemical methods that the co-display of four antigens is indeed achieved in single nanoparticles. Additionally, we have determined percentages of multivalent (mosaic) nanoparticles with four, three, or two HA proteins. The integrated imaging and physicochemical methods we have developed for single nanoparticle multivalency will serve to further understand immunogenicity data from our current FluMos-v1 clinical trial.
Keywords: ELISA; Fluorescence imaging; Fluorescent labeling; Influenza vaccine; Mass spectrometry; Nanoparticle; Size-exclusion chromatography; TIRFM.
. 2024 Feb 24;14(1):4534.
doi: 10.1038/s41598-024-54876-2. Mosaic quadrivalent influenza vaccine single nanoparticle characterization
Rong Sylvie Yang[SUP] #[/SUP][SUP] 1 [/SUP], Maria Traver[SUP] #[/SUP][SUP] 2 [/SUP], Nathan Barefoot[SUP] 1 [/SUP], Tyler Stephens[SUP] 3 [/SUP], Casper Alabanza[SUP] 1 [/SUP], Javier Manzella-Lapeira[SUP] 2 [/SUP], Guozhang Zou[SUP] 1 [/SUP], Jeremy Wolff[SUP] 1 [/SUP], Yile Li[SUP] 1 [/SUP], Melissa Resto[SUP] 1 [/SUP], William Shadrick[SUP] 1 [/SUP], Yanhong Yang[SUP] 1 [/SUP], Vera B Ivleva[SUP] 1 [/SUP], Yaroslav Tsybovsky[SUP] 3 [/SUP], Kevin Carlton[SUP] 1 [/SUP], Joseph Brzostowski[SUP] 2 [/SUP], Jason G Gall[SUP] 1 [/SUP], Q Paula Lei[SUP] 4 [/SUP]
Affiliations
- PMID: 38402303
- PMCID: PMC10894272
- DOI: 10.1038/s41598-024-54876-2
Recent work by our laboratory and others indicates that co-display of multiple antigens on protein-based nanoparticles may be key to induce cross-reactive antibodies that provide broad protection against disease. To reach the ultimate goal of a universal vaccine for seasonal influenza, a mosaic influenza nanoparticle vaccine (FluMos-v1) was developed for clinical trial (NCT04896086). FluMos-v1 is unique in that it is designed to co-display four recently circulating haemagglutinin (HA) strains; however, current vaccine analysis techniques are limited to nanoparticle population analysis, thus, are unable to determine the valency of an individual nanoparticle. For the first time, we demonstrate by total internal reflection fluorescence microscopy and supportive physical-chemical methods that the co-display of four antigens is indeed achieved in single nanoparticles. Additionally, we have determined percentages of multivalent (mosaic) nanoparticles with four, three, or two HA proteins. The integrated imaging and physicochemical methods we have developed for single nanoparticle multivalency will serve to further understand immunogenicity data from our current FluMos-v1 clinical trial.
Keywords: ELISA; Fluorescence imaging; Fluorescent labeling; Influenza vaccine; Mass spectrometry; Nanoparticle; Size-exclusion chromatography; TIRFM.